First Multicenter Clinical Trial on Machine Perfusion Preservation for Marginal Donor Kidney Transplantation in Japan
Transplantation Proceedings · 2023
DOI: 10.1016/j.transproceed.2023.03.043 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Transplantation Proceedings, 2023. Verfasst von Hitoshi Iwamoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Kidney Transplantation Surgery, Hachioji Medical Center, Tokyo Medical University, Tokyo, Japan. Electronic address: hitoiwa@tokyo-med.…. Hauptthemen laut MEDLINE: Kidney Transplantation, Tissue and Organ Procurement. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Machine perfusion has not been widely used because of its low demand in Japan; however, we believe its advantages may increase the number of organ transplants. METHODS: Here, we report the first clinical trial of machine perfusion for kidney transplantation in Japan. We used the CMP-X08 perfusion device (Chuo-Seiko Co, Ltd, Asahikawa, Hokkaido, Japan) to preserve the donated organs. The flow rate, perfusion pressure, renal resistance, and temperature were monitored during continuous hypothermic perfusion. RESULTS: From August 2020 to the present, 13 cases of perfusion-preserved kidney transplantation have been performed. Of these, ten and 3 cases were performed using organs donated after brain death (DBD) and cardiac death (DCD), respectively. The average age of the recipients was 55.9 ± 7.3 (45-66) years. The average dialysis period was 14.8 ± 8.4 (0-26) years. The donor's final creatinine level before organ retrieval was 1.58 ± 1.0 (0.46-3.07) mg/dL. The warm ischemic times of the 3 DCD donors were 3, 12, and 18 minutes. The average total ischemic time was 12.0 ± 3.7 (7.17-19.88) hours. The average MP time was 140 (60-240) minutes. A total of 7 cases had delayed graft function. The best creatinine level during hospitalization was 1.17 ± 0.43 (0.71-1.85) mg/dL. There were no primary non-functional cases, and perfusion preservation was safely performed in all cases. CONCLUSIONS: Therefore, we present this report as the first clinical trial on machine perfusion for kidney transplantation from marginal donors with DBD and DCD in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Kidney Transplantation Surgery, Hachioji Medical Center, Tokyo Medical University, Tokyo, Japan. Electronic address: hitoiwa@tokyo-med.ac.jp.
- Department of Hepato-biliary Pancreatic and Transplantation Surgery, Asahikawa Medical University, Hokkaido, Japan.
- Department of Kidney Transplantation Surgery, Hachioji Medical Center, Tokyo Medical University, Tokyo, Japan.
- Department of Surgery, Nephrology Center, Toranomon Hospital, Tokyo, Japan.
- Department of Surgery, Tohoku University, Sendai, Japan.
- Department of Urology, Okazaki Medical Center, Fujita Health University, Okazaki, Japan.
Zitieren
APA
Iwamoto, H., Matsuno, N., Konno, O., Nakamura, Y., Ishii, Y., Tokodai, K., Kashiwadate, T., Miyagi, S., Kusaka, M., Ito, T., & Kenmochi, T. (2023). First Multicenter Clinical Trial on Machine Perfusion Preservation for Marginal Donor Kidney Transplantation in Japan. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2023.03.043
Vancouver
Iwamoto H, Matsuno N, Konno O, Nakamura Y, Ishii Y, Tokodai K, et al. First Multicenter Clinical Trial on Machine Perfusion Preservation for Marginal Donor Kidney Transplantation in Japan. Transplantation Proceedings. 2023. doi:10.1016/j.transproceed.2023.03.043
BibTeX
@article{Iwamoto2023,
author = {Iwamoto, Hitoshi and Matsuno, Naoto and Konno, Osamu and Nakamura, Yuki and Ishii, Yasuo and Tokodai, Kazuaki and Kashiwadate, Toshiaki and Miyagi, Shigehito and Kusaka, Mamoru and Ito, Taihei and Kenmochi, Takashi},
title = {First Multicenter Clinical Trial on Machine Perfusion Preservation for Marginal Donor Kidney Transplantation in Japan},
journal = {Transplantation Proceedings},
year = {2023},
doi = {10.1016/j.transproceed.2023.03.043}
}
EUVIMED